Journal Mobile Options
Table of Contents
Vol. 85, No. 6, 2010
Issue release date: July 2010
Section title: Original Paper
Pharmacology 2010;85:328–335
(DOI:10.1159/000312686)

Cannabinoids Inhibit Cellular Respiration of Human Oral Cancer Cells

Whyte D.A. · Al-Hammadi S. · Balhaj G. · Brown O.M. · Penefsky H.S. · Souid A.-K.
Departments of aPediatrics and bPharmacology, State University of New York, Upstate Medical University, Syracuse, N.Y., and cPublic Health Research Institute, New Jersey, N.J., USA; dDepartment of Pediatrics, United Arab Emirates University, Faculty of Medicine and Health Sciences, Al Ain, United Arab Emirates

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/25/2010
Accepted: 1/4/2010
Published online: 6/2/2010

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: http://www.karger.com/PHA

Abstract

Background and Purpose: The primary cannabinoids, Δ9-tetrahydrocannabinol (Δ9-THC) and Δ8-tetrahydrocannabinol (Δ8-THC) are known to disturb the mitochondrial function and possess antitumor activities. These observations prompted us to investigate their effects on the mitochondrial O2 consumption in human oral cancer cells (Tu183). This epithelial cell line overexpresses bcl-2 and is highly resistant to anticancer drugs. Experimental Approach: A phosphorescence analyzer that measures the time-dependence of O2 concentration in cellular or mitochondrial suspensions was used for this purpose. Key Results: A rapid decline in the rate of respiration was observed when Δ9-THC or Δ8-THC was added to the cells. The inhibition was concentration-dependent, and Δ9-THC was the more potent of the two compounds. Anandamide (an endocannabinoid) was ineffective; suggesting the effects of Δ9-THC and Δ8-THC were not mediated by the cannabinoidreceptors. Inhibition of O2 consumption by cyanide confirmed the oxidations occurred in the mitochondrial respiratory chain. Δ9-THC inhibited the respiration of isolated mitochondria from beef heart. Conclusions and Implications: These results show the cannabinoids are potent inhibitors of Tu183 cellular respiration and are toxic to this highly malignant tumor.


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 1/25/2010
Accepted: 1/4/2010
Published online: 6/2/2010

Number of Print Pages: 8
Number of Figures: 3
Number of Tables: 0

ISSN: 0031-7012 (Print)
eISSN: 1423-0313 (Online)

For additional information: http://www.karger.com/PHA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Gaoni Y, Mechoulam R: Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646–1647.
  2. Neu R, Powers H, King S, Gardner LI: RΔ8- and Δ9-tetrahydrocannabinol: effects on cultured human leucocytes. J Clin Pharmacol New Drugs1970;10:228–230.
  3. McKallip RJ, Lombard C, Martin BR, Nagarkatti M, Nagarkatti PS: MΔ9-Tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Ther 2002;302:451–465.
  4. Baek SH, Kim YO, Kwag JS, Choi KE, Jung WY, Han DS: Boron trifluoride etherate on silica-A modified Lewis acid reagents (VII): antitumor activity of cannabigerol against human oral epitheloid carcinoma cells. Arch Pharm Res 1998;21:353–356.
  5. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H: Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008;68:339–342.
  6. Bifulco M, Laezza C, Pisanti S, Gazzerro P: Cannbinoids and cancer: pros and cons of an antitumor strategy. Br J Pharmacol 2006;148:123–135.
  7. Kogan NM: Cannbinoids and cancer. Mini Rev Med Chem 2005;5:941–952.
  8. Zhu W, Friedman H, Klein TW: Δ9-Tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J Pharmacol Experimental Therapeutics 1998;286:1103–1109.
  9. Batandier C, Leverve X, Fontainer E: Opening of the mitochondrial permeability transition pore induces reactive oxygen species production at the level of the respiratory chain complex I. J Biol Chem 2004;279:17197–17204.
  10. Sarafian TA, Kouyoumjian S, Khoshaghideh F, Tashkin DP, Roth MD: Δ9-Tetrahydrocannabinol disrupts mitochondrial function and cell energetics. Am J Physiol Lung Cell Mol Physiol 2003;284:L298–L306.
  11. Sacks PG, Parnes SM, Gallick GE, Mansouri Z, Lichtner R, Satya-Prakash KL, Pathak S, Parsons DF: Establishment and characterization of two new squamous cell carcinoma cell lines derived from tumors of the head and neck. Cancer Res 1988;15:2858–2866.
  12. Gibson S, Shillitoe E: Analysis of apoptosis-associated genes and pathways in oral cancer cells. J Oral Pathol Med 2006;35:146–154.
  13. Gibson S, Pellenz C, Hutchinson RE, Davey FR, Shillitoe EJ: Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector. Clin Cancer Res 2000;6:213–222.
  14. Yao L, Iwai M, Furata I: Correlations of bcl-2 and p53 expression with the clinicopathological features in tongue squamous cell carcinomas. Oral Oncol 1999;35:56–62.
  15. Whyte DA, Broton CE, Shillitoe EJ: The unexplained survival of cells in oral cancer: what is the role of p53? J Oral Pathol Med 2002;31:125–133.
  16. Tao Z, Withers HG, Penefsky HS, Goodisman J, Souid AK: Inhibition of cellular respiration by doxorubicin. Chem Res Toxicol 2006;19:1051–1058.
  17. Mahoney JM, Harris RA: Effect of Δ9-tetrahydrocannabinol on mitochondrial processes. Biochem Pharmacol 1972;21:1217–1226.
  18. Beyer RE: Preparation, properties, and conditions for assay of phosphorylating electron transport particles (ETPH) and its variations. Methods Enzymol 1967;10:186–194.
  19. Toro-Goyco E, Rodriguez MB, Preston AM: On the action of Δ9-tetrahydrocannabinol as an inhibitor of sodium- and potassium-dependent adenosine triphosphatase. Mol Pharmacol 1978;14:130–137.
  20. World Health Organization: The World Oral Health Report 2003. Geneva, World Health Organization, 2003, pp 6–7.
  21. Centers for Disease Control and Prevention: Preventing and controlling oral and pharyngeal cancer: recommendations from a national strategic planning conference. MMWR 1998;47:1–12.
  22. Munson AE, Harris LS, Friedman MA, Dewey WL, Carchman RA: Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975;55:597–602.
  23. Casanova ML, Blazquez C, Martinez-Palacio J, Villanueva C, Fernandez-Acenero MJ, Huffman JW, Jorcano JL, Guzman M: Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003;111:43–50.